Abstract：Objective: To observe the clinical efficacy of Shengxuening tablets to improve the law to maintain iron metabolism in hemodialysis patients with renal anemia and erythropoietin and its synergistic effect. Methods: 60 cases uremic patients with renal anemia selected as the research object, randomly divided into Shengxuening group and succinic acid ferrous group, 30 cases in each group. The patients of shengxuening group were given oral Shengxuening tablets, and oral ferrous succinate group was given Ferrous Succinate Tablets. In accordance with the guidelines, the patients of 2 groups were given the recommended dose individualized combination of erythropoietin treatment. After 16-weeks treatment, the clinical curative effect of the patients of 2 groups were observed and the changes of hemoglobin, hematocrit, serum ferritin and transferrin saturation were recorded before and after treatment in 2 groups. Meanwhile, the adverse reactions in the 2 groups were monitored. Results: After 16 weeks of treatment, the hemoglobin, hematocrit, serum ferritin, transferrin saturation of the 2 groups were increased compared with before treatment, the difference was statistically significant (P < 0.05). However, after treatment, the hemoglobin, hematocrit, serum ferritin, transferrin saturation of Shengxuening group was significantly higher than that of ferrous succinate group, the difference was statistically significant (P < 0.05). Compared with ferrous succinate group, Shengxuening group of adverse reaction is less. Conclusion: Compared with ferrous succinate group, Shengxuening can effectively supplement renal anemia in patients with uremia for iron, and less adverse reactions of blood safety.
马晓辉, 王海燕. 生血宁片治疗维持性血液透析患者肾性贫血的临床观察[J]. 河北医学, 2017, 23(11): 1905-1908.
MA Xiaohui. Clinical Observation of Shengxuening Tablets in the Treatment of Maintenance Hemodialysis Patients with Renal Anemia. HeBei Med, 2017, 23(11): 1905-1908.
[1] Port FK, Pisoni RL, Bragg-Gresham JL, et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States[J].Blood Purif, 2004, 22(1): 175~180. [2] Krairittichai U, Supaporn T, Aimpun P, et al. Anemiaand survival in thai hemodialysis patients: evidence from national registry data[J].Med Assoc Thai, 2006, 89(Suppl 2): S242~S247. [3] Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study(DOPPS)[J].Am Kidney Dis, 2004, 44(1): 94~111. [4] Eckardt KU, Scherhag A, Macdougal C, et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD[J].Am Soc Nephrol, 2009, 20(12): 2651~2660. [5] Locatelli F, Nissenson AR, Barrett BJ, et al. Clinicalpractice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from kidney disease: improving global outcomes[J].Kidney International, 2008, 74(10): 1237~1240. [6] Thorp ML, Johnson ES, Yang X, et al. Effect of anaemia onmortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease[J].Nephrology(Carlton), 2009, 14(2): 240~246. [7] KDIGO: Clinical Practice Guideline for Anemia in Chronic Kidney Disease[J].Kidney International Supplemengt, 2012, 2(4): 283~287. [8] Ware RE, Rees RC, Sarnaik SA, et al. Renal function in infants with sickle cell Anemia: baseline data from the baby HUG trial[J].The Journal of Pediatrics,2009, 156(1): 66~70. [9] 中国人民解放军肾脏病专业协作组. 2001例血液透析患者病因分析及高血压和贫血治疗状况[J].中国血液净化, 2005, 4(5): 235~238. [10] 徐丽霞, 梁馨苓, 李志莲, 等. 血液透析患者贫血相关因素分析[J].中国血液净化, 2014, 13(1): 5~7. [11] Portoles J, Lopez-Comez JM, Aljama P. On behalf of the MAR study group. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR study[J].Nephrol Dial Transplant, 2007, 22(2): 500~507. [12] National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000[J].Am Kidney Dis, 2001, 37(Suppl 1): 182~238. [13] Finkelstein FO, Story K, Firanek C, et al. Health related quality of life and hemoglobin levels in chronickidney disease patients[J].Clin Am Soc Nephrol, 2009, 4(1): 33~38. [14] 赵洪雯, 吴雄飞, 刘宏. 尿毒症毒素对大鼠培养骨髓细胞红细胞生成素受体的影响[J].重庆医学, 2003, 32(6): 678~681. [15] Drueke TB, Locatelli F, Clvne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia[J].N Eng Med, 2006, 355(20): 2071~2084. [16] 王蕴若, 陈茂杰, 王惠新. 静脉铁剂治疗维持性血液透析患者肾性贫血的疗效分析[J].实用临床医药杂志, 2010, 14(11): 67~68. [17] 何平, 苏晓晓, 杨旭, 等. 蔗糖铁对尿毒症患者肾性贫血疗效及对其微炎症状态的影响[J].中国临床药理学杂志, 2011, 27(11): 827~829.
2017, Vol. 23 
冀公网安备13080202000677号